NHSCSP Guidelines include DYSIS implementation
DYSIS included in NHSCSP Guidelines
NHS Cervical Screening Programme has updated its guidelines to include an implementation guide for DYSIS.
Edinburgh – 1st September 2012 – DYSIS Medical Ltd, the medical devices company in female health, today announced that its cervical cancer screening colposcopy technology has been included in the NHS Cervical Screening Programme (NHSCSP) implementation guidelines.
DYSIS colposcopy uses spectral imaging to help clinicians highlight any areas of concern by mapping out the condition of a woman’s cervix. In clinical trials, it has been shown to significantly boost sensitivity in detecting cervical cancer in its earliest stages. Armed with this additional information, clinicians are able to take immediate steps to treat patients and prevent disease progression.
The released document provides information on how DYSIS is successfully implemented in NHS clinics and covers all practical information from procurement to data integration.
Alastair Atkinson, DYSIS Medical CEO commented on the guidelines, “As a follow-up to the publication of the recommendation from NICE, the implementation guidelines from the NHSCSP is a welcome addition.”
For more information, please contact:
DYSIS Medical Ltd Tel: +44 (0)1506 592159
Alastair Atkinson, CEO
College Hill (PR for DYSIS Medical) Tel: +44 (0)20 7457 2020
Melanie Toyne Sewell / Gemma Howe
Notes to Editors
DYSIS Medical Ltd
DYSIS Medical Ltd has its global headquarters in Edinburgh. The company is committed to saving lives through the early detection and diagnosis of disease using biophotonic innovations. It aims to be the global leader in automated optical molecular imaging technologies for medical diagnostic and screening applications. For more information, please visit: www.dysismedical.com
The DYSIS cervical cancer screening product employs advanced photonics and computer assistance to quantify and map the aceto-whitening process – providing clinicians with reliable information to assist in the identification of pre-cancerous lesions. The product is sold in Europe and the US.